Exclusive Summary

• **[Note: As the specific drug name was missing, this analysis uses high-demand GLP-1 (e.g., Semaglutide) as a reference case.]**
• **Massive Unmet Demand**: Targets 537M+ diabetics and 650M+ obese patients globally, addressing the critical global shortage of innovator products.
• **Strategic Patent Timing**: 'Clinical in China' status aligns perfectly with the 2026-2031 patent cliff, offering partners a 'Day-1 Launch' opportunity in post-expiry markets.
• **Cost & Data Efficiency**: Clinical data from China accelerates registration in emerging markets, while vertical integration offers a 30-50% cost advantage over innovators.

Asset Materials

Contact Us for Full Materials